JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\ZNo1uUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUOyN|Yh|ryP MWfTRW5ITVJ?
H4 cell NEjUR4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWnCV4ZFUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFY4ODdizszN M4m2[3NCVkeHUh?=
KGN cell NFrDcYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2LTU2lvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NlA2KM7:TR?= M2e2WXNCVkeHUh?=
786-0 cell NWW4SZFuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkTMTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|I6QDlizszN Ml;jV2FPT0WU
769-P cell M17zVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4TLR2lvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgzOjJ2IN88US=> M1:2XnNCVkeHUh?=
K5 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF;KZ45KdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wNVYzPCEQvF2= NXX5[XQyW0GQR1XS
MLMA cell M3j3VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXTyV3ZKUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB|MkG3JO69VQ>? M4TNR3NCVkeHUh?=
MLMA cell NG\LenVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkK4O|A{KM7:TR?= MVnTRW5ITVJ?
EW-7 cell NHjXXXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmL0TY5pcWKrdHnvckBw\iCqdX3hckBGXy15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6zNlY6PSEQvF2= MV3TRW5ITVJ?
SW1088 cell NH7FSWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvqeWJKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDB4NUGg{txO NYjHdoNHW0GQR1XS
MC-IXC cell M3S2UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPDSWRKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDd5OUKg{txO MVLTRW5ITVJ?
NCI-H2052 cell NFr6Z|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPlS|hKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMEixOVch|ryP Mlf6V2FPT0WU
IGR-1 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XhUmlvcGmkaYTpc44hd2ZiaIXtZY4hUUeULUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlEzODJ6IN88US=> NXn3T5cyW0GQR1XS
DSH1 cell MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLoTY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yOFI6PiEQvF2= MYLTRW5ITVJ?
PA-1 cell MkPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzLTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zNFA2Qc7:TR?= MX3TRW5ITVJ?
SK-MEL-3 cell NXfOVGxlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3L[G1UUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwM{GyNFch|ryP MXvTRW5ITVJ?
SW900 cell M{\RNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zNXGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> M4C3eHNCVkeHUh?=
CAKI-1 cell M1PiPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI4OzhizszN M4LENXNCVkeHUh?=
ES1 cell NUTNdnNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlHQTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWyPFk4KM7:TR?= NYTRZmU6W0GQR1XS
SK-N-DZ cell NFS3eHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRGqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlYzPTl3IN88US=> MoXIV2FPT0WU
RH-1 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJHJJNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4OFY{KM7:TR?= NH3ZVGdUSU6JRWK=
ES8 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3z6ZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PVcxOiEQvF2= NHjITXVUSU6JRWK=
NEC8 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXnmSYJ{UW6qaXLpeIlwdiCxZjDoeY1idiCQRVO4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44Pjl6MjFOwG0> NFfQfZdUSU6JRWK=
LNCaP-Clone-FGC cell Mm\vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHnyco5KdmirYnn0bY9vKG:oIHj1cYFvKEyQQ3HQMWNtd26nLV\HR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDN3M{[g{txO M4XzS3NCVkeHUh?=
HCE-4 cell M2T5[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlLMTY5pcWKrdHnvckBw\iCqdX3hckBJS0VvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPVgxPyEQvF2= MlP2V2FPT0WU
U-118-MG cell NY\2bHI4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\2SJJNUW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMEGwOlYh|ryP MmjSV2FPT0WU
GI-ME-N cell Mm\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLtTY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDd7NjFOwG0> MmXVV2FPT0WU
LB1047-RCC cell Mm[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF4MUSzJO69VQ>? MV;TRW5ITVJ?
HT-1080 cell M1q1Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEHsPXJKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>? NFj0UHFUSU6JRWK=
NB69 cell M1PBXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M332OWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|UxPDdizszN MkXEV2FPT0WU
NCI-H1693 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTzbJFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNES4PVUh|ryP MUHTRW5ITVJ?
HSC-3 cell MlzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnnTTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFk6OzNizszN MkLqV2FPT0WU
MDA-MB-231 cell NUT6OYk2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIPNSnZKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW1PFk6KM7:TR?= Ml3vV2FPT0WU
HOS cell NUXnXoZpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkiwTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke4OlMh|ryP MYjTRW5ITVJ?
BT-549 cell NFHqZohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWHqPYtRUW6qaXLpeIlwdiCxZjDoeY1idiCEVD21OFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njd6OEeg{txO NWX4fnFSW0GQR1XS
NB17 cell M4fDPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfXTY5pcWKrdHnvckBw\iCqdX3hckBPSjF5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFk4PiEQvF2= MY\TRW5ITVJ?
5637 cell NGrEVWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGCxVpdKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc6PjV{IN88US=> MUfTRW5ITVJ?
OVCAR-8 cell NI\EfplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF7U[25KdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl{NEO2JO69VQ>? M325cXNCVkeHUh?=
G-402 cell M1fuSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{LDSWlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk{ODN3IN88US=> NGDy[3NUSU6JRWK=
BB30-HNC cell NFvsWJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXHaZ297UW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMEeyNVgh|ryP NX\1bWQ6W0GQR1XS
HCC1806 cell M2X6UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{i0N2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUiwOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODh|M{mg{txO NGL3XpVUSU6JRWK=
COLO-800 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4C5[2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF{NkSg{txO M17aXHNCVkeHUh?=
FADU cell M1rGfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWHFdpFnUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PjV3NzFOwG0> NIXvN4ZUSU6JRWK=
NCI-H1651 cell NVfWO5g2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? Ml3XV2FPT0WU
AGS cell MlLTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNEe3NVEh|ryP NWjafY5WW0GQR1XS
CHP-212 cell NF7teIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=> NVzCSnpIW0GQR1XS
YAPC cell MkPOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJHlCWENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O|EyKM7:TR?= Mn\lV2FPT0WU
GOTO cell NYrENZgxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoHSTY5pcWKrdHnvckBw\iCqdX3hckBIV1SRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60PVU4PiEQvF2= NX:1NWJiW0GQR1XS
KYSE-510 cell M2TuSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrlTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=> NXr4TW1pW0GQR1XS
NCI-H2342 cell NVLCTmtVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLLXGNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUOyO|gh|ryP NWe3NnN5W0GQR1XS
BFTC-905 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLOUmVCUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkK4N|Uh|ryP NGHoWGJUSU6JRWK=
EW-16 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63NlA6OyEQvF2= NU\JNIZrW0GQR1XS
SK-MEL-30 cell NFPac5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHHabW5KdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{S1OFMh|ryP NEjnSJNUSU6JRWK=
HLE cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmjTTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3OFg6KM7:TR?= M{HobXNCVkeHUh?=
T98G cell Mn3nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7afZNKdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6PjN3IN88US=> Mn[yV2FPT0WU
HUTU-80 cell NXriUnkyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFezfGZKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh2MkK4JO69VQ>? NWfmc5FWW0GQR1XS
NOS-1 cell NHi1bXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUTFcmFKUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTR5Nk[g{txO NHS4OlVUSU6JRWK=
SW780 cell NXr5UGJzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHHOdGxKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46Pjl2OTFOwG0> MWTTRW5ITVJ?
KYSE-180 cell MmjxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnGPVFKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{[1OEDPxE1? NXvwbmxvW0GQR1XS
MDA-MB-361 cell M4e3ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7KWGZTUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= MUnTRW5ITVJ?
SNU-C2B cell NFex[VNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mor0TY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF|ODFOwG0> NHPPSm9USU6JRWK=
NCI-H661 cell NHLsVm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPzW4ppUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwME[5OEDPxE1? NXP3WHlRW0GQR1XS
OE33 cell MoDTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4fXS2lvcGmkaYTpc44hd2ZiaIXtZY4hV0V|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVQ{QDlizszN MVvTRW5ITVJ?
TYK-nu cell Ml:3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmrMTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ|IN88US=> MXTTRW5ITVJ?
COLO-792 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> M4\QRnNCVkeHUh?=
HEL cell NX7HbYM5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2e1dGlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6yOlc3KM7:TR?= M4nI[XNCVkeHUh?=
D-566MG cell NGL2dlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH;CeFNKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN|NEmxJO69VQ>? MmLhV2FPT0WU
U031 cell MkfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUGwe3ZnUW6qaXLpeIlwdiCxZjDoeY1idiCXMEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OThzNjFOwG0> NYX0R3RjW0GQR1XS
COR-L23 cell NYDGZ3Q{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkDyTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0> M17PNHNCVkeHUh?=
NCI-H2452 cell M1mz[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkH6TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK0OVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjV{MkixJO69VQ>? MljqV2FPT0WU
BB65-RCC cell MoCyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NY[1Z2Q6UW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNkS1PUDPxE1? MWTTRW5ITVJ?
CAL-33 cell NGnMTFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4rhcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PTZ4NTFOwG0> M3nKc3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development, L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID